Duragesic Pediatric Exclusivity Decision Expected “Shortly,” Mylan Says
Mylan expects to hear from FDA "shortly" on whether its generic version of Johnson & Johnson's Duragesic fentanyl patch will be delayed an additional six months due to a pediatric exclusivity extension
You may also be interested in...
The launch timing for the first generic version of Johnson & Johnson/Alza's Duragesic fentanyl patch will depend on FDA's decision about a six-month pediatric exclusivity extension for the product
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials